During the first three quarters of 2023, these medicines helped the pharmaceutics research and development outfit top the GDP of its homeland, Denmark. This performance also catapulted Novo Nordisk to the top spot among European companies. Wegovy, the weight loss drug, raked in sales of $4.5bn, increasing the overall sales of this segment by 154%.…
Read more
Sales of Novo Nordisk’s (NVO) diabetic drug, Ozempic, escalated by more than $1bn between its $2.3bn in Q3 2022 and $3.5bn in Q3 2023. Yahoo Finance noticed the absence of any discussions around GLP-1s at two conferences. A JPMorgan analyst, who attended a healthcare conference in January 2024, viewed this as good news for the…
Read more
On Sunday, 17th December, industry experts noted that while the firm has grown rapidly in 2023, keeping momentum throughout 2024 will be noticeably harder, with investors predicting only a 9% upside on average for next year. Portfolio manager at Antipodes Partners, Nick Cameron, noted 2024 investor predictions: [Novo is] an excellent R&D company, and they’re…
Read more